Now, you can advance from specimen to report in a single day with a hands-off, automated, simple, next-generation sequencing (NGS) workflow. This will enable you to combine your lab’s immunohistochemistry (IHC) results with timely NGS insights to deliver a complete, relevant report in as little as one day.
• Mutations, copy number variations (CNVs), and fusion variant types across 50 key genes such as EGFR, ALK, BRAF, ROS1, RET, KRAS, PIK3CA, and ERBB2, among others
• One-day workflow, with only two user touchpoints and 20 minutes of hands-on time
• Only 10 ng of DNA or RNA required, allowing for more samples to be tested
• Compatible with formalin-fixed, paraffin-embedded (FFPE) tissue as well as liquid biopsy samples
Unmatched ease of use with minimum hands-on time and no expertise required
The set-up-and-go workflow of the Genexus System makes NGS accessible even if your lab is new to the technology. It integrates and automates nucleic acid extraction quantification, library preparation, sequencing, and analysis reporting under a single software ecosystem. With less operational hands-on time (only 20 minutes with two touchpoints) compared to current technologies, the Genexus System can help improve every lab’s productivity as well as reduce potential handling errors.
Single-day turnaround—get results in the same amount of time as other techniques, such as IHC
Other NGS technologies, as well as the traditional way of sending out or outsourcing samples, can take weeks to obtain results, which may delay answers. With the Genexus System, you can go from a biological specimen to a report in just one day. In addition, the system has the ability to analyze small sample batches cost effectively—reducing your need for batching, and empowering you to deliver results faster than ever.
Minimum sample input and maximum sample success rate
Tissue is still the issue in oncology research, with a large proportion of samples having very small amounts of tissue or being of inferior quality. Some NGS technologies require large amounts of sample, leading to more than one out of four samples being unusable for sequencing. The Oncomine Precision Assay, based on Ion Torrent™ AmpliSeq™ HD technology, requires only 10 ng of DNA or RNA, resulting in more than 95% of samples producing sequencing results.
Oncomine Precision Assay